Explore
Validate
Learn
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2638 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- AR Antibody
- Antibody type
- Monoclonal
- Antigen
- Amino acids 299-315 (STEDTAEYSPFKGGYTK) from human Androgen Receptor were used as the immunogen for the AR antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- AR441
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the AR antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.
Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression.
Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation.
Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.
Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, Amano S, Nemoto N
Medical molecular morphology 2016 Mar;49(1):11-21
Medical molecular morphology 2016 Mar;49(1):11-21
HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Guo W, Wang W, Zhu Y, Zhu X, Shi Z, Wang Y
International journal of clinical and experimental pathology 2015;8(7):8008-17
International journal of clinical and experimental pathology 2015;8(7):8008-17
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E
Journal of clinical pathology 2015 Oct;68(10):839-43
Journal of clinical pathology 2015 Oct;68(10):839-43
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.
Rodrigues DN, Hazell S, Miranda S, Crespo M, Fisher C, de Bono JS, Attard G
Histopathology 2015 May;66(6):898-901
Histopathology 2015 May;66(6):898-901
Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression.
Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, Ud Din N, Purgina B, Lai C, Griffith CC, Chiosea SI
The American journal of surgical pathology 2015 May;39(5):705-13
The American journal of surgical pathology 2015 May;39(5):705-13
Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y, Yoshida A, Yoshida M, Takahashi M, Tsuta K
Pathology international 2015 Jun;65(6):286-92
Pathology international 2015 Jun;65(6):286-92
'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation.
Agaimy A, Lell M, Schaller T, Märkl B, Hornung J
Histopathology 2015 Jan;66(2):182-91
Histopathology 2015 Jan;66(2):182-91
Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA, Abd-Elazeem MA
Annals of diagnostic pathology 2015 Feb;19(1):37-42
Annals of diagnostic pathology 2015 Feb;19(1):37-42
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 15;21(24):5460-8
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 15;21(24):5460-8
Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, Rose C, Jernström H
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Aug 15;21(16):3640-50
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Aug 15;21(16):3640-50
Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.
Iobagiu C, Lambert C, Raica M, Lima S, Khaddage A, Peoc'h M, Genin C
Cancer genetics 2015 Apr;208(4):135-42
Cancer genetics 2015 Apr;208(4):135-42
No comments: Submit comment
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of formalin-fixed, paraffin-embedded human prostate carcinoma stained with AR antibody (AR441).
